Sugi Predict

Sugi Predict / Compounds / Fludarabine

Fludarabine

Fludarabine

SCHEMBL4455725

Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O.O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F.O=c1[nH]cc(F)c(=O)[nH]1.OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADA

The experimentally established mechanism targets of Fludarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.47
▸ NT5E P21589 2/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ DTYMK P23919 4/20 0.41
▸ DNMT1 P26358 3/20 0.41
▸ FPR2 P25090 2/20 0.41
▸ DNMT3B Q9UBC3 2/20 0.41
▸ CA5A P35218 1/20 0.40
▸ PNP P00491 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.38
▸ ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fludarabine SCHEMBL2441566 0.87 LMNA (0.62) LMNANT5EHIF1ASMN1; SMN2CA5A
Fludarabine SCHEMBL158659 0.85 LMNA (0.65) LMNANT5EHIF1ASMN1; SMN2DTYMK
Fludarabine Phosphate SCHEMBL28142252 0.83 CA5A (0.59) LMNANT5EHIF1ASMN1; SMN2DTYMK
Pentostatin SCHEMBL5159567 0.82 LMNA (0.48) LMNASMN1; SMN2DNMT1ADORA3ADORA2A
Pentostatin SCHEMBL724965 0.81 LMNA (0.66) LMNASMN1; SMN2ADORA3ADORA2A
Fludarabine SCHEMBL726385 0.80 NT5E (0.74) LMNANT5EHIF1ACA5AADORA3
Fludarabine SCHEMBL17080291 0.80 LMNA (0.49) LMNANT5EHIF1ASMN1; SMN2DNMT1
Fludarabine Phosphate SCHEMBL28177481 0.79 CA5A (0.52) LMNANT5EHIF1ASMN1; SMN2DTYMK
Fludarabine Phosphate SCHEMBL27849470 0.79 CA5A (0.68) LMNANT5EHIF1ASMN1; SMN2DTYMK
Fludarabine Phosphate SCHEMBL27702599 0.79 CA5A (0.52) LMNANT5EHIF1ASMN1; SMN2DTYMK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1883407-A4 COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS COMBINATORX INC (US) 2009-07-01 — — EP disclosed
EP-1883407-A1 COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS CombinatoRx, Incorporated (US) 2008-02-06 — — EP disclosed
WO-2007041463-A2 ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 — — WO disclosed
WO-2007041593-A2 ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 — — WO disclosed
WO-2007041584-A2 IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 — — WO disclosed
WO-2007041677-A2 SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 — — WO disclosed
WO-2006122007-A1 COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS COMBINATORX, INCORPORATED (US) 2006-11-16 — — WO disclosed
EP-1545544-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS Combinatorx, Incorporated (US) 2005-06-29 — — EP disclosed
WO-2004006842-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 — — WO disclosed
WO-2004007676-A2 COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 — — WO disclosed
WO-2004006906-A2 METHODS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 — — WO disclosed